New study aims to spot hidden cancer spread in lobular breast cancer

NCT ID NCT07635654

Not yet recruiting Knowledge-focused Sponsor: KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test whether whole-body MRI scans and blood tests for tumor DNA can better detect cancer progression in a type of breast cancer that is often missed by standard scans. Researchers will follow 43 people with metastatic invasive lobular carcinoma for up to 30 months, comparing the new methods with usual care. The goal is to see if these tools help doctors make better treatment decisions and improve patient access to trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better monitoring of metastatic lobular breast cancer, helping doctors detect progression earlier and allowing more patients to qualify for clinical trials.
What could go wrong: This is a small, early-stage observational study (43 people) that is not yet recruiting. It tests imaging and blood tests, not a treatment, so it will not directly improve outcomes. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE LOBULAR BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Lobular invasive lobular breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INVASIVE LOBULAR BREAST CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.